Purchase this article with an account.
D. A. Della Rocca, E. A. Maher, J. P. Milite, M. G. Plagianos, S. M. Ahmad, E. Moy, P. E. Scherer, P. A. Latkany, R. C. Della Rocca; The Adipokine Adiponectin Can Be Elevated in Graves’ Ophthalmopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5562.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
A transgenic mouse model with overexpression of the adipokine adiponectin resulted in progressive expansion of the retrobulbar fat pad leading to fulminant exophthalmos. We undertook a pilot study to determine if adiponectin levels in patients with Graves’ Ophthalmopathy are elevated as found in the transgenic mouse model.
From a large urban ophthalmic plastics service 46 consecutive patients with Graves' Ophthalmolopathy had their mean serum adiponectin levels determined through an adiponectin ELISA. Clinical data was recorded using standardized criteria.
An ANOVA analysis found that mean adiponectin levels differed significantly between inactive and active Graves' disease patients (p=0.0458) and presence of diabetes (p=0.0054). Mean adiponectin level in the active disease group was 15.78 mg/L (SD=8.51), and in the inactive group it was 11.36 mg/L (SD=6.29).
The adipokines such as adiponectin warrant further investigation regarding its role in the development of Graves’ ophthalmopathy and its clinical subtypes and concomitant diseases such as diabetes.
This PDF is available to Subscribers Only